Menu
Image thumbnail

SEBiotic® (Bacillus coagulans LBSC)

Shelf-stable probiotic to promote gut and immune health*

Science & Research

  • “A Prospective, Interventional, Randomized, Double-blind, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of Bacillus Coagulans LBSC Capsule in the Treatment of Acute Diarrhea with Abdominal Discomfort and Flatulence.” Clinical.
  • “A Prospective, Interventional, Randomized, Double-blind and Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bacillus coagulans LBSC in Subjects with Irritable Bowel Syndrome.” Clinical.
  • “Impact of a Gastrointestinal Stable Probiotic Supplement Bacillus coagulans LBSC on Human Gut Microbiome Modulation.” Clinical/in vitro, 2020.
  • “Efficacy and Safety of Bacillus coagulans LBSC in Drug Induced Constipation Associated With Functional Gastrointestinal Disorder: A Double-Blind, Randomized, Interventional, Parallel, Controlled Trial a Clinical Study on Bacillus coagulans LBSC for Drug Induced Constipation Associated With FGIDs.” Clinical.
  • “Genome Based Safety Assessment for Bacillus coagulans Strain LBSC (DSM 17654) for Probiotic Application.” In vitro.
  • “Effect of High Pressure Processing (HPP) on Spore Preparation of Probiotic Bacillus coagulans LBSC [DSM 17654].” In vitro.
  • “Process and Storage Stability of Bacillus coagulans LBSC in Food Matrices and Appraisal of Calorific Restriction.” In vitro.
  • “Stability of Bacillus coagulans LBSC and Effect on Sensory Attributes in Tortillas, Tortilla Chips, and Chocolate.” In vitro.
  • “Clinical Efficacy and Safety of DigeSEB Super PB on Gastrointestinal Health in Adult Population: A Randomized, Double-Blind, Placebo-Controlled, Parallel Study.” Clinical, not yet published.
  • “A Prospective, Interventional, Randomized, Double-Blind, Parallel, Multi-Arm, Controlled, Phase 2 Clinical Study to Evaluate the Efficacy and Safety of ProbioSEB CSC3 in Overweight and Obese Subjects with the Risks of Type 2 Diabetes Mellitus.” Clinical, not yet published. Prospective, interventional, randomized, double-blind, parallel, controlled, clinical study.
  • “Immunomodulatory Properties of Probiotic Complex ProbioSEB CSC3 in Healthy Adults: A Prospective, Interventional, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Clinical Study.” Clinical, not yet published. Prospective, interventional, randomized, double-blind, parallel, controlled, clinical study.
  • “Potential of the Combination of a Systemic Enzyme Complex and Probiotics Administration to Combat COVID-19: A Randomized Open Label Prospective Analysis.” Clinical, Open-label, randomized, comparative, parallel-group, and controlled study.
  • “A Randomized, Multicentric, Double Blind, 2-Arm, Placebo-Controlled, Prospective Study to Investigate the Safety and Efficacy of the Health Supplements ImmunoSEB + ProbioSEB CSC3 on Patients Suffering from COVID-19 Induced Fatigue/Post Viral Fatigue Syndrome.” Clinical.
  • “Management of Post COVID-19 Fatigue Using Systemic Enzymes and Probiotics – Case Series.” Case Series. Eight patients experiencing fatigue post discharge from COVID-19 hospitalization were treated with ImmunoSEB (BD) and ProbioSEB CSC3 (OD) for 14 days.
  • “A Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of Dietary Supplement Pepzyme Pro on the Digestion and Absorption of Whey Protein.” Clinical.
  • “A Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of Dietary Supplement Pepzyme Pro on the Digestion and Absorption of Pea Protein.” Clinical.
  • “A Prospective, Interventional, Randomized, Double-Blind, Parallel, Multi-Arm, Controlled, Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SlimSEB in Overweight and Obese Subjects with the Risks of Type 2 Diabetes Mellitus.” Clinical, not yet published.
  • “A Single Blind, Placebo-Controlled Case Study to Determine Efficacy of SlimSEB as Adjuvant Therapy in Presence of GLP-1 Agonist Drug in Diabetic Adults.” Case Study, not yet published.
  • “A Single Blind, Placebo Controlled Case Study to Determine Effect of GlucoSEB on Carbohydrate Digestion Thereby Attaining Slow or Low Glucose Release in Diabetic Adults – Case Study.”